ZZZuleykha A. Zalyalova

Zuleykha A. Zalyalova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zuleykha A. Zalyalova has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Consensus on definitions, terminology, classification of dystonia, and clinical guidelines. Part 1. Historical context, definitions, terminology, and clinical characteristics (Axis i)

    by Z.A. Zalyalova, D.V. Zakharov, V.A. Tolmacheva, E.A. Antipenko, N.G. Zhukova, O.R. Orlova, S.N. Illarioshkin, A.A. Tomsky, A.A. Gamaleya, V.L. Golubev

    Objective. This study analyzes current international approaches to the definition, terminology, classification, and clinical phenomenology of dystonia, adapts the 2025 international consensus for Russian clinical practice, and develops a unified Russian-language terminological standard. Material and methods. A panel of ten Russian movement disorder experts developed the consensus. The analysis included the 2013 and 2025 international consensus statements, clinical guidelines, and publications on the classification, phenomenology, pathophysiology, genetics, and treatment of dystonia indexed in PubMed and Web of Science (2013—2026). Terminology, definitions, and practical recommendations were established through expert discussions. Results. An adapted Russian-language version of the 2025 international consensus on Axis I of the clinical classification of dystonia is presented. The current disease definition, terminological standards, clinical phenomena, and accompanying signs of dystonia have been clarified. Terms not recommended for use have been identified, and algorithms for clinical assessment and differential diagnosis are proposed. Contemporary approaches to symptomatic therapy are outlined, with botulinum toxin type A recommended as first-line therapy for most focal and segmental forms of dystonia. Conclusions. This consensus unifies terminology and clinical assessment of dystonia, adapts international guidelines for Russian-speaking practice, and supports standardized diagnosis, phenomenological description, and rational therapy selection.

  • Multimodal biomarkers of Parkinson’s disease risk in essential tremor. (A prospective cohort study)

    by S.E. Munasipova, Z.A. Zalyalova

    Objective. To identify clinical and neuroimaging biomarkers associated with Parkinson’s disease (PD) onset in patients with essential tremor plus (ET-plus) during prospective observation. Material and methods. This prospective observational cohort study included 159 patients diagnosed with essential tremor (ET), ET-plus, ET-PD, and idiopathic PD. The median observation period was 4.6 years. All participants underwent standardized neurological examinations and assessments, including the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III), Montreal Cognitive Assessment (MoCA), Scale for the Assessment and Rating of Ataxia (SARA), Unified Dystonia Rating Scale (UDRS), Fahn-Tolosa-Marin Tremor Rating Scale, Non-Motor Symptoms Scale (NMSS), olfactory testing, screening for probable REM sleep behavior disorder (RBD), Stroop test, forward and backward counting tests, Boston Naming Test, literal and semantic verbal fluency tests, transcranial sonography (TCS) of the substantia nigra, and magnetic resonance imaging (MRI) with nigrosome-1 assessment. Results. Conversion from ET-plus to PD occurred in 15 patients. The most significant predictors of conversion were hyperechogenicity of the substantia nigra on transcranial Doppler (TCD), absence of nigrosome-1 on MRI, probable REM sleep behavior disorder (RBD), and ET duration greater than 20 years. The predictive model demonstrated high discriminatory power (C-statistic 0.89). Clinically, patients who converted showed a combination of non-motor symptoms, cognitive decline, signs of nigrostriatal dysfunction, and more frequent resting tremor. Conclusions. The risk of Parkinson’s disease onset in patients with ET-plus is determined by a combination of multimodal biomarkers. The prospective identification of 15 patients who converted supports classifying this subgroup as a high-risk phenotype that warrants ongoing monitoring and comprehensive evaluation.

  • Consensus on definitions, terminology, classification of dystonia, and clinical guidelines. Part 2. Etiology and pathogenesis (Axis II). Novel genetic classification

    by Z.A. Zalyalova, D.V. Zakharov, V.A. Tolmacheva, E.A. Antipenko, N.G. Zhukova, O.R. Orlova, S.N. Illarioshkin, A.A. Tomsky, A.A. Gamaleya, V.L. Golubev

    This article presents an adapted Russian-language version of the 2025 International Consensus on the Classification of Dystonia, with particular emphasis on etiology and pathogenesis (Axis II). The revised classification integrates recent advances in the understanding of the biological mechanisms underlying dystonia. Axis II distinguishes between genetic and acquired etiologies, clarifies the anatomical classification of nervous system lesions, and introduces a new category for pathogenetic mechanisms, including developmental, degenerative, metabolic, and immune or inflammatory processes. The article highlights the adoption of the modern genetic nomenclature (Movement Disorder Society — MDS), which replaces the previous DYT locus system. A detailed analysis is provided for the pathogenetic mechanisms of drug-induced, autoimmune, and neurodegenerative forms of dystonia. The final section outlines etiopathogenetic therapies, including incobotulinum toxin A and neurosurgical interventions. The proposed two-axis system aims to systematize clinical data and improve the accuracy of dystonia diagnosis for both specialists and physicians in related fields.

  • Non-motor manifestations in patients with cervical dystonia. A literature review and results of a pilot single-arm study on the efficacy of a fixed-dose combination of mirtazapine and tizanidine (Dorsumio) in the management of non-motor manifestations in patients with cervical dystonia

    by Z.A. Zalyalova

    The article presents a literature review of non-motor disorders and the results of a single-arm interventional study evaluating the effects of Dorsumio on pain and affective manifestations in cervical dystonia. Although cervical dystonia is traditionally considered a motor disorder, contemporary studies highlight a high prevalence of its non-motor manifestations, which significantly determine the patients’ quality of life. The use of botulinum toxin type A does not always correct non-motor disorders. Furthermore, the use of conventional antidepressants (selective serotonin reuptake inhibitors) is limited due to the risk of worsening dystonic hyperkinesis. The combination of mirtazapine (exhibiting anxiolytic and analgesic properties) and tizanidine (a central muscle relaxant) may exert a synergistic effect on pain and affective syndromes. Objective. To evaluate the safety and efficacy of a fixed-dose combination of mirtazapine (15 mg) and tizanidine hydrochloride (6 mg) (Dorsumio) for the management of pain, anxiety, and depression in patients with cervical dystonia receiving stable botulinum toxin type A therapy. Material and methods. A single-arm interventional study was conducted, which included 22 patients (19 women, 3 men; mean age 51±2.9 years) with cervical dystonia. All patients regularly received botulinum toxin type A injections with a confirmed positive effect on motor manifestations (evaluated by the TWSTRS scale). In cases where non-motor symptoms (such as pain, anxiety, low mood) persisted, Dorsumio was additionally prescribed at a dose of 1 tablet in the evening for a 2-month course. Pain assessment was performed using the Visual Analogue Scale (VAS), while anxiety and depression were evaluated using the Hospital Anxiety and Depression Scale (HADS). Statistical analysis was performed using the paired Student’s t test and the Wilcoxon signed-rank test. Results. Against the background of botulinum toxin type A therapy in combination with Dorsumio, a significant reduction in motor manifestations of cervical dystonia (clinical improvement) was noted (TWSTRS score: 42.77±9.80 before treatment vs. 33.64±8.37 after treatment; difference: 9.14±1.04; p<0.001). The addition of Dorsumio led to a statistically significant reduction in: pain on the VAS (from 7.05±1.62 points to 4.27±1.67 points; p<0.01), anxiety on the HADS (from 12.67±1.80 points to 8.42±2.08 points; p<0.001), and depression on the HADS (from 7.14±2.40 points to 5.76±1.93 points; p<0.01). Adverse events (somnolence in 13.6% of patients, dry mouth in 23.0% of patients, and increased appetite in 23.0% of patients) were mild and did not lead to treatment discontinuation. Conclusion. Analysis of the literature data on the structure of mental, sensory, and dyssomnic disorders in cervical dystonia showed that anxiety-depressive disorders occur in 20—63.6% of cases, obsessive-compulsive disorders in 6.7—21.1% of cases, pain syndrome in up to 88.9% of cases, and insomnia in 65—72% of cases. The fixed-dose combination of mirtazapine and tizanidine (Dorsumio) can be considered a safe and effective adjunct therapy option for the management of pain syndrome and affective disorders in patients with cervical dystonia who have persistent non-motor disorders despite adequate motor correction with botulinum toxin type A. The obtained data warrant confirmation in randomized controlled trials.

  • Dystonia caused by a mutation in the KMT2B gene

    by Z.A. Zalyalova, A.N. Khabibrakhmanov

    Dystonia due to the KMT2B mutation (DYT-KMT2B) is a relatively common cause of progressive generalized dystonia in children; it can potentially account for up to 10—20% of cases of generalized dystonia with early onset. However, only one case of DYT-KMT2B has been reported In Russia to date. Determining the genetic variant and assessing clinical manifestations can help identify this dystonia and determine the indications for drug treatment, including botulinum therapy and neurosurgical intervention. We present a clinical case of a girl with a DYT-KMT2B onset at the age of 6 years and a review of the literature.


  • Familial hemifacial spasm

    by Z.A. Zalyalova, D.M. Khasanova, A.A. Rogozhin, A.F. Akhatov, I.A. Khasanov

    Hemifacial spasm (HFS) is a hyperkinetic disorder predominantly associated with neurovascular conflict (NVC). The article presents a clinical case of familial HFS in three females from successive generations (age of onset 25—28 years). In two patients, the onset was associated with childbirth. MRI revealed an NVC in one patient, while in the other two, it was absent or the findings were inconclusive. ENMG showed signs of demyelination in one patient and hyperactivity of the blinking reflex in another, confirming the role of ephaptic transmission. A possible hereditary predisposition is discussed, including anatomical features of the posterior fossa and genetic factors. Familial cases of HFS require further study to clarify the etiology and pathogenesis.

  • Parkinson’s Disease and Pregnancy. Resolution of The National Society for the Study of Parkinson’s Disease and Movement Disorders

    by E.V. Bril, O.E. Turgunkhujaev, N.G. Dudchenko, A.A. Gamaleya, N.G. Zhukova, Z.A. Zalyalova, O.S. Zimnyakova, S.N. Illarioshkin, E.A. Katunina, T.K. Kulua, et al.

    Traditionally, Parkinson’s disease is considered a disease of old age. However, in 5—10% of patients, it is detected before the age of 40 years. This age is included in the childbearing period. Beliefs of the unwantedness of pregnancy, its impossibility, or the high risks associated with delivery are common. However, data on the course of pregnancy are limited and conflicting. Therefore, the development of evidence-based recommendations is an urgent task. In recent years, new data have been obtained regarding the course of pregnancy in patients with Parkinson’s disease, which are presented in this article.

  • Open Access

    Parkinson's disease and migraine

    by Z. A. Zalyalova, E. A. Katunina, D. V. Pokhabov

    Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Migraine is the most prevalent neurological condition among adults. It has been established that migraine often precedes the development of PD, and with the onset of motor symptoms and/or the initiation of specific therapy, both the frequency and severity of migraine attacks significantly decrease. It is likely that the two conditions share common functional and biochemical characteristics. If brainstem nuclei disintegration and dopaminergic neurotransmission dysregulation are involved in the pathogenesis of migraine, then studying patients with migraine who go on to develop PD may provide important insights into the role of dopamine and/or dopaminergic brainstem regions in the pathogenesis of both migraine and PD. This review focuses on studies addressing epidemiology, the role of dopaminergic system genes in migraine development, mechanisms linking the two diseases, and the impact of pharmacological therapy.


  • Art and creativity in Parkinson’s disease: the mysterious effects of dopamine

    by E.A. Katunina, Z.A. Zalyalova, D.V. Pokhabov, I.A. Putyatin

    The article is devoted to the phenomenon of the emergence or enhancement of creative abilities during therapy in some patients with Parkinson’s disease (PD). The article discusses the possible pathogenetic causes of this phenomenon, the connection with impulsive-compulsive disorders (ICD). All PD patients who are addicted to one type of creativity are characterized by increased motivation, forcing them to spend hours doing what they love, the time of which coincided with the start of dopaminergic therapy. There is a fine line between the emerging «passion» for art and CAVIAR, which is determined by the dose of Antiparkinsonian drugs, genetic characteristics, and personal characteristics. The issue of the emergence of creativity in the work of patients with PD remains controversial, and most studies indicate a deterioration in divergent thinking, which is a criterion for creativity. The results of the observation of artists suffering from PD showed changes in the style of their work against the background of the disease, the appearance of an emphasis on color, changing the brightness and spectrum of the color palette, moving to more abstract images. Among the factors that can influence creative activities, such as pre—existing skills or abilities in relation to a particular type of art, taking dopaminergic drugs, their dose, the preservation of cognitive functions, family support, and the social environment are discussed.


  • Open Access

    Rapid eye movement sleep behavior disorder: modern concept and Parkinson’s disease correlation

    by Diana M. Khasanova, Zuleykha A. Zalyalova, Guzal R. Ilina, Nailya I. Bagdanova, Залялова Зулейха Абдуллазяновна

    This review describes the association between rapid eye movement (REM) sleep behavior disorder (RBD) and synucleinopathies, primarily Parkinson's disease. This article reviews the diagnostic criteria, the epidemiology of RBDs, their pathogenesis, and their association with early non-motor symptoms. The data are presented to assess the risk of phenoconversion of RBDs to Parkinson's disease or other synucleinopathies such as Lewy body dementia and multiple system atrophy. A prodromal period of RBDs may precede synucleinopathies years or decades before potential manifestation of motor, cognitive, or autonomic disorders, and this may be important for initiating the neuroprotective therapy. Other causes of RBDs are also reviewed.